<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE nitf SYSTEM "http://www.nitf.org/IPTC/NITF/3.3/specification/dtd/nitf-3-3.dtd">
<nitf change.date="June 10, 2005" change.time="19:30" version="-//IPTC//DTD NITF 3.3//EN">
  <head>
    <title>BIOTECHNOLOGY COMPANY HURT</title>
    <meta content="MB012659" name="slug"/>
    <meta content="19" name="publication_day_of_month"/>
    <meta content="10" name="publication_month"/>
    <meta content="2000" name="publication_year"/>
    <meta content="Thursday" name="publication_day_of_week"/>
    <meta content="Business/Financial Desk" name="dsk"/>
    <meta content="1" name="print_page_number"/>
    <meta content="W" name="print_section"/>
    <meta content="5" name="print_column"/>
    <meta content="Health; Business" name="online_sections"/>
    <docdata>
      <doc-id id-string="1240097"/>
      <doc.copyright holder="The New York Times" year="2000"/>
      <series series.name="WORLD BUSINESS BRIEFING: EUROPE"/>
      <identified-content>
        <classifier class="indexing_service" type="descriptor">Venereal Diseases</classifier>
        <classifier class="indexing_service" type="descriptor">Finances</classifier>
        <classifier class="indexing_service" type="descriptor">Vaccination and Immunization</classifier>
        <classifier class="indexing_service" type="descriptor">Tests and Testing</classifier>
        <classifier class="indexing_service" type="descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="indexing_service" type="descriptor">Human Papilloma Virus (Hpv)</classifier>
        <org class="indexing_service">Cantab Pharmaceuticals</org>
        <org class="indexing_service">Smithkline Beecham</org>
        <person class="indexing_service">Cowell, Alan</person>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Business</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Business/World Business</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Classifieds/Job Market/Job Categories/Banking, Finance and Insurance</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Classifieds/Job Market/Job Categories/Pharmaceutical, Biotechnology and Science</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Health</classifier>
        <classifier class="online_producer" type="general_descriptor">Vaccination and Immunization</classifier>
        <classifier class="online_producer" type="general_descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="online_producer" type="general_descriptor">Venereal Diseases</classifier>
        <classifier class="online_producer" type="general_descriptor">Viruses</classifier>
        <classifier class="online_producer" type="general_descriptor">Tests and Testing</classifier>
        <classifier class="online_producer" type="general_descriptor">Finances</classifier>
        <classifier class="online_producer" type="general_descriptor">Diseases and Conditions</classifier>
        <classifier class="online_producer" type="general_descriptor">Medicine and Health</classifier>
      </identified-content>
    </docdata>
    <pubdata date.publication="20001019T000000" ex-ref="http://query.nytimes.com/gst/fullpage.html?res=9504E5DA123EF93AA25753C1A9669C8B63" item-length="66" name="The New York Times" unit-of-measure="word"/>
  </head>
  <body>
    <body.head>
      <hedline>
        <hl1>BIOTECHNOLOGY COMPANY HURT</hl1>
      </hedline>
      <byline class="print_byline">By Alan Cowell</byline>
      <byline class="normalized_byline">Cowell, Alan</byline>
      <abstract>
        <p>Shares of British biotechnology company Cantab Pharmaceuticals plummet 67 percent, to 76.5 pence ($1.11) after it says genital-wart vaccine called TH-GW failed in tests; company says SmithKline Beecham has stopped work on drug; graph (S)</p>
      </abstract>
    </body.head>
    <body.content>
      <block class="lead_paragraph">
        <p>Shares in the British biotechnology company Cantab Pharmaceuticals plummeted 67 percent, to 76.5 pence ($1.11), after it said a genital-wart vaccine called TH-GW had failed in tests. The company said the pharmaceuticals giant SmithKline Beecham had stopped work on the drug after tests showed no improvement over standard therapies.</p>
        <p>Alan Cowell</p>
      </block>
      <block class="full_text">
        <p>Shares in the British biotechnology company Cantab Pharmaceuticals plummeted 67 percent, to 76.5 pence ($1.11), after it said a genital-wart vaccine called TH-GW had failed in tests. The company said the pharmaceuticals giant SmithKline Beecham had stopped work on the drug after tests showed no improvement over standard therapies.</p>
        <p>Alan Cowell</p>
        <p>WORLD BUSINESS BRIEFING: EUROPE</p>
      </block>
    </body.content>
  </body>
</nitf>
